Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel complement inhibitors.

M K Liszewski1, J P Atkinson

  • 1Department of Medicine, Washington University School of Medicine, 660 South Euclid, Box 8045, St Louis, MO 63110, USA.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade.

Human molecular genetics·2021
Same author

Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Complement regulators in human disease: lessons from modern genetics.

Journal of internal medicine·2014
Same author

Complement receptor structure and function.

Immunology today·2014
Same author

The 20 faces of the fourth component of complement.

Immunology today·2014
Same author

Human C3b- and C4b-regulatory proteins: a new multi-gene family.

Immunology today·2014
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

The complement system aids immunity but can harm tissues. Researchers are developing complement inhibitors to treat diseases like Alzheimer's and autoimmune disorders, with several agents in clinical trials.

Area of Science:

  • Immunology
  • Molecular Medicine

Background:

  • The complement system is crucial for innate and adaptive immunity, mediating microbial defense and inflammation.
  • Its dysregulation contributes to various autoimmune diseases, neurodegenerative disorders, and transplant rejection.
  • A significant portion of complement proteins are regulators, highlighting the system's potent tissue-damaging capacity.

Purpose of the Study:

  • To review the role of the complement system in disease pathogenesis.
  • To highlight the unmet need for therapeutic complement inhibitors.
  • To discuss current and emerging strategies for complement inhibition.

Main Methods:

  • Literature review of complement system function and dysregulation in disease.
  • Analysis of current therapeutic approaches targeting complement activation.

Related Experiment Videos

  • Overview of ongoing clinical trials and future directions in complement inhibition.

    • Main Results:

    • The complement system's dual role in host defense and pathology is established.
    • Numerous conditions, including autoimmune diseases (e.g., lupus), neurodegeneration (e.g., Alzheimer's disease), and transplant rejection, are linked to complement overactivation.
    • Several therapeutic strategies, including soluble regulators, antibodies, small molecules, and xenotransplantation approaches, are under development.

    Conclusions:

    • Complement inhibitors represent a promising therapeutic avenue for a range of debilitating conditions.
    • Ongoing research and clinical trials are paving the way for effective complement-targeted therapies.
    • Successful complement inhibition could revolutionize the treatment of immune-mediated and inflammatory diseases.